NewLink re-evaluating Phase III plans for indoximod combo in melanoma

NewLink Genetics Corp. (NASDAQ:NLNK) said it will not start the randomized, placebo-controlled portion of the Phase III Indigo301 trial to evaluate indoximod (NLG8189) plus anti-PD-1 mAbs Keytruda pembrolizumab or Opdivo nivolumab to treat

Read the full 330 word article

How to gain access

Continue reading with a
two-week free trial.